



## **Alkermes to Present at the 44th Annual J.P. Morgan Healthcare Conference**

December 30, 2025

DUBLIN--(BUSINESS WIRE)--Dec. 30, 2025-- [Alkermes plc](#) (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 44<sup>th</sup> Annual J.P. Morgan Healthcare Conference. The presentation will take place on Tuesday, Jan. 13, 2026 at 10:30 a.m. PST (1:30 p.m. EST/6:30 p.m. GMT). The live webcast may be accessed under the Investors tab on [www.alkermes.com](http://www.alkermes.com) and will be archived for 14 days.

### **About Alkermes plc**

Alkermes plc (Nasdaq: ALKS), a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes' website at [www.alkermes.com](http://www.alkermes.com).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20251229760927/en/): <https://www.businesswire.com/news/home/20251229760927/en/>

Alkermes Contact:  
Jamie Constantine  
Investor Relations  
+1 781 873 2402

Source: Alkermes plc